Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis

References

• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• ZouWChenLInhibitory B7-family molecules in the tumour microenvironmentNat Rev Immunol20088646747718500231
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015372431131925482239
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIkedaTEfficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancerJ Clin Oncol20143215 suppl5511
   Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFCheckMate 025 InvestigatorsNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVKEYNOTE-006 InvestigatorsPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRKEYNOTE-001 InvestigatorsPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• McDermottDFSosmanJASznolMAtezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia studyJ Clin Oncol201634883384226755520
   PubMed Web of Science ®Google Scholar
• FehrenbacherLSpiraABallingerMPOPLAR Study GroupAtezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLancet2016387100301837184626970723
   PubMed Web of Science ®Google Scholar
• RizviNBrahmerJOuS-HISafety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)Proc Am Soc Clin Oncol20153315 suppl abstr8032
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• PostowMAManaging immune checkpoint-blocking antibody side effectsAm Soc Clin Oncol Educ Book2015768325993145
   PubMedGoogle Scholar
• Abdel-RahmanOElHalawaniHFouadMRisk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysisExpert Opin Drug Saf201514101507151826394770
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementInt J Surg20108533634120171303
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials1986731771883802833
   PubMedGoogle Scholar
• LauJIoannidisJPSchmidCHQuantitative synthesis in systematic reviewsAnn Intern Med199712798208269382404
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol201331561662223295794
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• KimKWRamaiyaNHKrajewskiKMIpilimumab associated hepatitis: imaging and clinicopathologic findingsInvest New Drugs20133141071107723408334
   PubMed Web of Science ®Google Scholar
• HofmannLForschnerALoquaiCCutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyEur J Cancer20166019020927085692
   PubMed Web of Science ®Google Scholar
• EigentlerTKHasselJCBerkingCDiagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treat Rev20164571826922661
   PubMed Web of Science ®Google Scholar
• BendellJCPowderlyJDLieuCHSafety and efficacy of MPDL3280A (antiPDL1)in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC)J Clin Oncol20153315s
   Google Scholar
• AminAPlimackERInfanteJRNivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)J Clin Oncol2014325s
   PubMed Web of Science ®Google Scholar
• El-KhoueiryABMeleroICrocenziTSPhase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040J Clin Oncol20153315s
   Web of Science ®Google Scholar
• DavarDWilsonMPrucknerCKirkwoodJMPD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIVCase Rep Oncol Med2015201573738926448890
   PubMed Web of Science ®Google Scholar
• NaidooJPageDBLiBTToxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnn Oncol201526122375239126371282
   PubMed Web of Science ®Google Scholar